PROCESS FOR PREPARING (S)-TETRAHYDRO-A-(1-METHYLETHYL)-2-OXO-1(2H)- PYRIMIDINEACETIC ACID
    8.
    发明公开
    PROCESS FOR PREPARING (S)-TETRAHYDRO-A-(1-METHYLETHYL)-2-OXO-1(2H)- PYRIMIDINEACETIC ACID 审中-公开
    制备(S) - 四氢-A-(1-甲基乙基)-2-氧-1(2H) - 嘧啶乙酸的方法

    公开(公告)号:EP1513819A1

    公开(公告)日:2005-03-16

    申请号:EP03727812.4

    申请日:2003-05-28

    IPC分类号: C07D239/10

    CPC分类号: C07D239/10

    摘要: A process for preparing (S)-tetrahydro-a-(1-methylethyl)-2-oxo-1(2H)-pyrimidineacetic acid, an intermediate that is useful in the synthesis of HIV protease inhibitors such as, for example, those described in US-5 914 332, is described.The process under consideration comprises the following steps:- L-valine is reacted with acrylonitrile;- the N-(2-cyanoethyl)-L-valine thus obtained is isolated and then reacted with an alkyl chloroformate;- the N-(2-cyanoethyl)-N-(alkoxycarbonyl)-L-valine thus obtained is hydro-genated in the presence of a hydrogenation catalyst, preferably rhodium;- the N-(3-aminopropyl)-N-(methoxycarbonyl)-L-valine thus obtained is cyclized to give the desired compound.

    摘要翻译: 制备(S) - 四氢-α-(1-甲基乙基)-2-氧代-1(2H) - 嘧啶乙酸的一种方法,一种可用于合成HIV蛋白酶抑制剂的中间体,例如描述于 描述的方法包括以下步骤: - 使L-缬氨酸与丙烯腈反应; - 分离由此获得的N-(2-氰乙基)-L-缬氨酸,然后与 烷基氯甲酸酯; - 由此获得的N-(2-氰乙基)-N-(烷氧羰基)-L-缬氨酸在加氢催化剂,优选铑存在下加氢; --N-(3-氨丙基)-N - (甲氧羰基)-L-缬氨酸环化得到所需化合物。

    PROCESS FOR THE PREPARATION OF PROTECTED 1-(1-AMINOALKYL)-OXIRANES
    9.
    发明公开
    PROCESS FOR THE PREPARATION OF PROTECTED 1-(1-AMINOALKYL)-OXIRANES 审中-公开
    制造方法PROTECTED 1-(1-氨基烷基)-OXIRANEN

    公开(公告)号:EP1339667A1

    公开(公告)日:2003-09-03

    申请号:EP01970067.3

    申请日:2001-09-27

    摘要: A method is described for the preparation of a compound of formula (formula see on enclosed paper version) where R is a protective group of the amino groups of the amino acids; R' is a C1-C10 alkyl radical, an aryl, an aralkyl or a group ArX(CH2)m; where Ar is an aryl, X = O, S, NR'; R' is a C1-C5 alkyl or aryl radical and m is an integer between 0 and 5; in which (a) the carboxyl group of a compound of formula (formula see on enclosed paper version) is activated by treatment with a group that is an activator of carboxyl groups; (b) the compound thus activated is made to condense with a trimethylsulphoxonium or tri-methylsulphonium ylide; (c) the keto-ylide thus obtained is reduced by reaction with a ketone-reducing agent; (d) the compound thus obtained is then cyclized to give the compound of formula IV by reaction with a base.